NMSU students win awards for research at National Diversity in STEM Conference – New Mexico State University NewsCenter

January 9, 2020 medical

Date: 01/06/2020Writer: Amanda Adame, 575-646-7953, aadame4@nmsu.edu Facebook Twitter LinkedIn Google+ Pinterest

Four New Mexico State University students in the College of Arts and Sciences were honored at the Society for the Advancement of Chicanos/Hispanics and Native Americans in Science (SACNAS) awards at The 2019 National Diversity in STEM Conference in Honolulu in November. The awards recognize the next generation of underrepresented researchers and Science, Technology, Engineering and Math (STEM) leaders while also giving visibility to their research and schools.

The student researchers represented areas of study from sociology to biology and chemistry and biochemistry as well as conservation ecology.

We are proud to see our students presenting their research at the largest multidisciplinary and multicultural STEM event in the country, said Enrico Pontelli, dean of the College of Arts and Sciences. SACNAS has a solid history of serving the purpose of engaging and encouraging underrepresented students in the STEM fields.

Daniel Aguirre, who is conducting research in NMSUs Department of Chemistry and Biochemistry, presented a poster in the chemistry category titled, In-Silico Dual Specificity Protein Phosphatase Differentiation Via Molecular Dynamic Simulations. His presentation included research about Dual Specificity Protein Phosphatases and if they play a role in the development of cancer, obesity and autoimmunity.

Isabella Terrazas, who is studying microbiology, presented about her research Cortical Granule Motility in Response to Hormone Stimulation during Sea Star Meiosis. She is studying how fertilization and proper development is required for sperm to bind. This activation of Rho, G proteins and actin, cell division plays a role in promoting translocation of cortical granules (CGs) to the cell surface.

Valerie Brewer, who is studying conservation ecology, presented her research Effects of Urbanization on Extra-Pair Paternity in the Song Sparrow. She explored how urbanization can affect the behavior of free-living animals. Preliminary results suggested that there are higher rates of extrapair offspring and nests in rural areas compared to urban.

Riva Silver, an unclassified student, presented her sociological research Exploring the Pathway Model Connecting Water and Education in West Texas Colonias Using Quasi-Youth Participatory Action Research; A Mixed Methods Approach. Through youth participatory action research, the study explored the connection between water infrastructure and high school graduation rates in unincorporated communities in rural areas that dont have access to city water and sewer services. The results suggest improved water infrastructure increases quality of life and education, which promotes higher high school graduation rates.

The students were among 82 graduate and undergraduate underrepresented groups in sciences. These awards also help encourage students to continue pursing STEM fields. The organization serves a community of over 20,000 supporters, more than 6,000 members and more than 115 student and professional chapters throughout the United States and Puerto Rico.

The SACNAS National Diversity in STEM Conference partners with institutions by providing a venue where students and professionals are able to enhance their science communication skills. As a multidisciplinary scientific society, the opportunity to present research to a general scientific audience fosters skills needed to not only build public support for science but also ensure that science is accessible to everyone. Through the awards, we recognize and celebrate presenters that make STEM inclusive, said Sonia Zrate, SACNAS President.

To learn more about SACNAS and the presentations by NMSU students visit sacnas.org.

Biochemistry

Researchers study the effects of antidepressants to identify the least harmful drugs – News-Medical.net

January 9, 2020 medical

About one in ten women in Qubec will suffer from depression during pregnancy. Without treatment, the illness carries risks for both mother and child. Yet antidepressants are not without consequences for fetal development. The team of professor Cathy Vaillancourt at the Institut National de la Recherche Scientifique (INRS) is studying the effects of these drugs in order to identify the least harmful ones.

Professor Vaillancourt, in collaboration with the teams of Professors J. Thomas Sanderson and Nicolas Doucet of the INRS, has just modeled for the first time the interaction of commonly used antidepressants with estrogen, and more specifically with the enzyme that synthesizes the estrogen: aromatase. It is an important contribution, since estrogen production is essential to the development of the fetus and to the mother's physiological adaptation during pregnancy. The results of their study were recently published in The Journal of Steroid Biochemistry and Molecular Biology.

Prescribing antidepressants for pregnant women is controversial. Studies show that, when administered to mothers during pregnancy, some of these treatments are associated with a risk of heart and lung malformations in newborns. Others are thought to result in impaired cognitive development, including autism, in children.

The harmful effects of antidepressants are thought to be due to their interaction with certain key hormones. Most antidepressants prescribed to pregnant women target serotonin, a hormone produced both in the brain and, as shown by Professor Vaillancourt's team in 2017, in the placenta. This is the family of antidepressants called selective serotonin reuptake inhibitors (SSRIs) such as Zoloft, Celexa or Prozac. However, estrogen would also be targeted by these treatments.

We wanted to see how the antidepressants that have been developed to block the serotonin transporter also affect aromatase. Using molecular models, we found that all the antidepressants we analyzed seemed to be able to bind directly to the enzyme and regulate its activity. This remains to be confirmed and the precise mechanism needs to be further investigated."

Cathy Vaillancourt, lead author of the study

Her doctoral student tested the effect of different types of antidepressants on placenta samples collected after delivery. "The antidepressants we chose to test are those most commonly prescribed in pregnant women, namely sertraline (Zoloft), venlafaxine (Effexor), fluoxetine (Prozac), paroxetine (Paxil), and citalopram (Celexa)," says Andre-Anne Hudon Thibeault "By comparing different doses and molecules, we were able to uncover some of their specificities."

By observing the effects of antidepressants on the placenta's hormonal system, the team can determine in advance if there will be a risk for the fetus. "Fetal development is strongly linked to the placenta. Every healthy fetus has a healthy placenta," maintains Vaillancourt.

Not all types of antidepressants have these harmful effects. Not all pharmacological molecules have the same hormonal affinity. "Depending on its form, a molecule may not interact the same way with estrogen and may therefore be less harmful to the developing fetus," asserts Professor Vaillancourt, who specializes in the involvement of maternal exposure to environmental and drugs factors in the endocrinology of the human placenta.

It's more a matter of the pharmacological molecule being administered and the dosage. "By testing several types of antidepressants at varying doses, our work will contribute to better choices regarding the type of antidepressant and the dose prescribed for pregnant women, while minimizing the side effects on the course of pregnancy and on fetal development," says Andre-Anne Hudon Thibeault, primary author and recent PhD graduate of INRS.

Discontinuing medication isn't always advisable. Depression can have serious consequences if left untreated. "Depression is one of the leading risk factors for suicide in pregnant women," says Vaillancourt. "Some studies suggest that depression can also compromise fetal development, due in part to poor lifestyle habits."

At the same time, Professor Vaillancourt is collaborating with a team of researchers in Vancouver who are studying a cohort of pregnant women and following their children over the long term. "This will give us a nice map of the various effects in women and the consequences for children's heart and brain development," says Vaillancourt. "We're still in the early stages of the project, but I'm confident that some antidepressants are safer and others can be developed for use during pregnancy."

Source:

Journal reference:

Thibeault, A-A. H., et al. (2019) Serotonin and serotonin reuptake inhibitors alter placental aromatase. The Journal of Steroid Biochemistry and Molecular Biology. doi.org/10.1016/j.jsbmb.2019.105470.

Read the original here:
Researchers study the effects of antidepressants to identify the least harmful drugs - News-Medical.net

Biochemistry

Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO – Yahoo Finance

January 9, 2020 medical

LEXINGTON, Mass., Jan. 9, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment of Dr. Jennifer Buell to President and COO.

Dr. Jennifer Buell, President & COO of Agenus

"Jen's tenure with Agenus, her exceptional leadership and cultural attributes, and her deep understanding of our science and operations makes her the top candidate for this newly created position," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. He added, "I am very excited to partner with Jen as we set to realize Agenus' vision of defeating cancer in the coming years."

After her tenure at Harvard Clinical Research Institute, Dr. Buell rejoined Agenus in 2013 as the Head of Global R&D operations. She was subsequently appointed as Chief Communications and External Affairs Officer, and then, to the position of Chief Operating Officer.

Dr. Buell brings over 20 years of biopharmaceutical industry experience and knowledge. Her efforts in the rapid advancement of discovery candidates through development has resulted in Agenus' record of advancing 13 I-O candidates to the clinic in the past four years. Her experience also includes extensive communication with internal and external constituencies, regulators, investors, and collaborators. Dr. Buell's previous operational and research experience include her tenures at Bristol-Myers Squibb and Harvard Clinical Research Institute. Dr. Buell obtained her PhD in Cellular, Biochemical, and Molecular Biochemistry with an MS in Biostatistics from Tufts University in Boston.

About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit http://www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' clinical development plans and timelines, the vision of defeating cancer in the coming years, and the expected contributions of Dr. Buell. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Story continues

See the article here:
Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO - Yahoo Finance

Biochemistry

Persistent TB infection of macrophages puts the brakes on immune engines, study shows – News-Medical.net

January 9, 2020 medical

Scientists from Trinity College Dublin have discovered both how TB puts the brakes on our immune engines and how we can kick-start those engines back into gear - providing hope that improved treatment options could soon be on the horizon.

Although ancient, TB is still the world's deadliest infectious disease. While it is rampant in Africa, the growing problem of antibiotic resistance is posing a significant threat worldwide.

Part of TB's success as a pathogen is because of its ability to infect the cells of our immune system, which are normally tasked with responding to the infection. It infects our lung macrophage cells and then manipulates them to its benefit - creating a safe home for it to hide out unperturbed, sometimes for years.

As part of an SFI-funded Starting Investigator Research Grant, Frederick Sheedy, Ussher Assistant Professor in the School of Biochemistry and Immunology at Trinity, mentored by St James' Hospital TB specialist, Professor Joseph Keane, has been examining how these lung macrophage immune cells fuel the fight against infection.

The work has been at the forefront of showing how the simple sugar glucose is used to promote the macrophages anti-bacterial activities.

In surprising results, published this week in leading international journal Cell Reports, Dr Emer Hackett (a PhD candidate in Professor Sheedy's group) found that persistent infection of these macrophages with TB puts the brakes on the glucose-fuelled engine. This essentially shuts down our natural response to infection, which allows the bacteria to hide out unperturbed.

Specifically, Dr Hackett found a small RNA molecule (which comprises tiny pieces of genetic information) which the bacteria promotes and which targets key enzymes that act as pumps in our immune engines to commit glucose to promote the anti-bacterial response.

When the bacteria promotes this small RNA molecule, which is termed microRNA-21, these enzyme pumps are removed from the engine and glucose is not used in the same way. This then allows the bacteria to escape and thrive.

Although this newly identified pathway is corrupted by the bacteria, the study also yielded some hope for the future.

Professor Sheedy explained:

We found that when TB-infected cells are treated with a key 'Interferon gamma protein signal' which is normally produced following vaccination, they will remove this microRNA to effectively relieve the brake and restore our normal immune response.

What is particularly promising from a societal impact perspective is that as well as increasing our knowledge of how TB corrupts our normal immune response to infection, our identification of the microRNA-21 means that scientists should be able to develop improved immunotherapies or vaccine strategies to help in the fight against TB infection."

Source:

Journal reference:

Hackett, E.E., et al. (2020) Mycobacterium tuberculosis Limits Host Glycolysis and IL-1 by Restriction of PFK-M via MicroRNA-21. Cell Reports. doi.org/10.1016/j.celrep.2019.12.015.

See the rest here:
Persistent TB infection of macrophages puts the brakes on immune engines, study shows - News-Medical.net

Embryology

Reproductive Biology Associates Announces Opening of New Location in Cartersville, Georgia – PRNewswire

January 8, 2020 medical

This 2,000 square-foot, state-of-the-art facility offers a full range of comprehensive diagnostic and treatment services for women and men, including consultations, ultrasounds, bloodwork, as well as semen analysis, saline infusion sonohysterograms and OB checks. This expansion marks the seventh location for RBA, which also has offices in metro Atlanta, Cumming, Fayetteville, Lawrenceville, Marietta and Piedmont.

The new location will be spearheaded by RBA's renowned physicians, who boast more than 200 years of cumulative experience in the diagnosis and treatment of infertility and have achieved in excess of 30,000 babies.Joining the award-winning team of reproductive endocrinologists is Dr. Monica Best, who has spent her career caring for patients in the Atlanta market.

"RBA has a solid reputation as being the area's leader in reproductive healthcare, giving each patient an individualized treatment plan that offers the latest in reproductive technologies," says Andrew A. Toledo, M.D., CEO of RBA. "Our expansion into the Cartersville area allows us to reach more patients who are looking to build their families through compassionate, best-in-class fertility service and care."

In addition to its geographical expansion, RBA also recently launched its R-Baby-Assuranceprogram, a financial guarantee program that gives eligible patients who are seeking in vitro fertilization (IVF) services the opportunity to pay a flat fee with the guarantee that they will take a baby home, or they are provided a full refund.

Since its inception in 1983, RBA has remained steadfast in its commitment to the development of revolutionary technologies and techniques to enhance pregnancy outcomes. RBA's specialized treatment plans combine compassionate patient care with state-of-the-art technology, much of which its physicians pioneered.

The new RBA facility is located at 962 Joe Frank Harris Parkway, Suite 206 in Cartersville, Georgia. A grand opening celebration is scheduled for February 2020.

For more information about RBA, visit https://rbaivf.com/.

About Reproductive Biology AssociatesFounded in 1983 and based in Atlanta, RBA is the oldest continuously operating full-service private fertility treatment center in the United States and is led by reproductive endocrinologistsDaniel B. Shapiro, MD; Andrew A. Toledo, MD;andZsolt Peter Nagy, PhD, who specializes in embryology. Since its establishment, the center's mission has focused on the development, improvement, and application of clinical and applied sciences to improve fertility care, with its RBA team being responsible for several notable firsts in reproductive medicine.

In 2016, RBA joined forces with Lee Equity Partners, serial entrepreneur Martn Varsavsky, and MyEggBank North America to establish Prelude, a comprehensive fertility company that is now the fastest growing network of fertility centers in the United States (Prelude Network). Preludehelps patients achieve their best possible pregnancy outcomes through access to top-tier centers, including RBA, and more than 30 internationally recognized reproductive endocrinologists, placing emphasis on the best clinical protocols and scientific advancements and sharing these best practices across its network.

About InceptionInception was founded in 2015 with an ambitious goal to create a family of organizations intent on improving the way patients experience their fertility journey. The company's mission is to shift the paradigm of the fertility market by raising the standard of care, streamlining fragmented components into an integrated system, and enhancing the overall patient experience. Inception's network of full service fertility centers, The Prelude Network, is now the largest of its kind including some of the country's top-tier fertility practices in 17 markets across the US.www.inceptionllc.com / http://www.aspirefertility.com

MEDIA CONTACT:Amanda SchlusselKrupp Kommunicationsaschlussel@kruppnyc.com

SOURCE The Prelude Network (Prelude)

https://www.inceptionllc.com/

The rest is here:
Reproductive Biology Associates Announces Opening of New Location in Cartersville, Georgia - PRNewswire

Embryology

Cheryl Tweedy is considering sperm donation to have more children but how does it work? – Yahoo News

January 8, 2020 medical

Cheryl Tweedy has revealed she could look to sperm donation to grow her family [Photo: Getty]

Cheryl Tweedy has revealedplans to have more children by sperm donor.

The pop singer, 36, explained that she wants to provide more than one sibling for two-year-old son Bear, who she shares with ex-boyfriend Liam Payne, 26.

Speaking to The Times Magazine, the star, who is currently single, said that the thought of potential solo fertility treatment makes me very happy.

She continued: If time was on my side and I was in my twenties, yeah, I would wait and consider more options, or wait for somebody I felt was right, but

You could meet somebody and for that year it feels incredible, but there is never a guarantee because there are so many variables that can happen.

Life is a funny old game.

Cheryl, went on to confirm that she is considering having a second and possibly third child with the help of a sperm donor from out of town.

She explained: You can get it from abroad.

Do you imagine some guy from Newcastle saying, Thats my child!?

Theres a lot to choose from and a lot to think about, she added.

READ MORE: What is spurgling and why do experts have concerns about the sperm stealing practice?

Cheryl Tweedy certainly isnt alone in considering fertility treatment without a father.

Latest figures from the Human Fertilisation and Embryology Authority (HFEA) showthe number of women attempting to start a family without a father increased by more than a third (35%) in two years; 1,272 women registered to have fertility treatment without a partner in 2016 up from 942 in 2014.

Likewise, there has been a rise in the use of sperm donation to start or grow a family. In 2016, 4,306 treatment cycles involved a patient using their own eggs and donor sperm, up 15% from 3,749 in 2015.

So why is sperm donation becoming more popular?

Some experts believe women are feeling more empowered to make that choice, while Dr Geetha Venkat director ofHarley Street Fertility Clinic believes the fact that many women are waiting until they are older to have children, and the changing circumstances surrounding starting a family are both contributing to the process becoming a more popular option.

Story continues

Of course sperm donation is also considered by some couples where the male partner has sperm abnormalities, poor sperm production or no sperm at all.

Some men carry inherited genetic diseases and are thus seeking donated sperm so as not to transmit the disease to their children, Dr Venkat continues.

Sperm donors can change lives and make families a reality.

READ MORE: Single mum, 39, who used sperm donor, explains choice to her baby boy in moving video

According to Dr Venkat there is a shortage of sperm donors in the UK and many people have to wait to benefit from donated sperm.

Some couples are fortunate enough to have friends and family willing to donate sperm as a known donor, she explains.

However, most are not so fortunate and thus they are likely to be in the queue waiting for around one year on average for sufficient donors to volunteer to donate their sperm.

Dr Venkat says that to meet the demand, over 500 sperm donors are needed every year from all nationalities, religions, ethnicities and cultures.

UK fertility clinics are able to import sperm from overseas, but only under certain conditions, she adds.

Dr Venkat says the person/people who receive a sperm donation will be the childs legal and social parent(s) the donor will not be named on the birth certificate.

The donor has no legal, financial or social obligations to any child created from the donation either now or in 18 years time, she explains.

Donors are asked to complete an HFEA form and this details personal details about them that could be handed to the donor-conceived person when they reach age 18 or older.

This information enables the childs parents to talk to them about their origins as they grow up and helps them build a mental picture of the donor, but they cannot meet them, she adds.

Its worth nothing that if youre having treatment at a licensed fertility clinic in the UK, the donor will have no legal rights or responsibilities to any children born with their sperm.

This is a personal choice, says Dr Venkat. But the most important thing is that donor procedures are carried out and that only healthy, safe sperm is used for your health and that of any child you have.

If you use a donor through a fertility clinic can find out:

height, weight, eye and hair colour

the year and country of birth

their ethnicity

whether they had any children at the time of donation, how many and gender

their marital status and medical history

they may choose to write a message at the time of their donation but you wont be able to find out any information that might reveal who the donor is.

READ MORE:Woman considers divorcing husband who fathered 47 children through sperm donations

When fertility treatment involves directly inserting sperm into a woman's womb, it is called Intrauterineinsemination (IUI).

The donor sperm is prepared in the laboratory to separate fast moving sperm from more sluggish or non-moving sperm, advises Dr Venkat.

The sperm is washed in the laboratory before insemination in order to concentrate the best sperm into a small amount of fluid.

Dr Venkat explains that using a catheter, your doctor will place the concentrated sperm directly into your uterus through your cervix, under ultrasound guidance.

The insemination procedure is relatively painless and is performed in a few minutes, although some women may experience some temporary, menstrual-like, cramping, she says.

IUI treatment can be performed in a natural cycle without fertility medicines or in a stimulated cycle with fertility drugs.

Though the treatment is available on the NHS, the waiting list can be very long in some areas and there are strict rules.

Dr Venkat advises speaking to your GP about your personal situation.

To give you an idea of costings, prices for IUI start at 1,100 per cycle with the HSFC.

Though you can go abroad for sperm donor treatment, like Cheryl Tweedy seems to hint shes considering, Dr Venkat says suggests remaining in the UK for the safest option.

The success rate with IUI treatment depends on your partner fertility status and your age.

Most couples who opt to undergo IUI have a 5 to 20%chance of becoming pregnant with each attempt, Dr Venkat says.

The chances are higher for stimulated IUI cycles in younger women using good quality sperm. However, it is not uncommon for multiple IUI cycles to be attemptedduethe poor success rate with a single cycle.

Link:
Cheryl Tweedy is considering sperm donation to have more children but how does it work? - Yahoo News

Embryology

Shady Grove Fertility (SGF) New York Announces Nine Upcoming Patient Education Events in its New Manhattan Location, Hosted by Drs. Anate Brauer and…

January 8, 2020 medical

Shady Grove Fertility (SGF), home to 85,000 babies born and 8,000 babies born from donor egg treatment, is opening its doors to introduce its SGF New York physicians and discuss how SGF New York helps individuals and couples start or grow their families.

NEW YORK, Jan. 8, 2020 /PRNewswire-PRWeb/ -- Physicians from Shady Grove Fertility (SGF) New York will host nine free educational events this January, February, and March, including three fertility seminars, three donor egg treatment seminars, and three egg freezing seminars.

Attendees can unwind with refreshments during informal, physician-led seminars and question-and-answer sessions with leading experts in infertility.

SGF New York's fertility seminars will cover infertility basics, including menstrual cycle warning signs, common causes of infertility, how infertility is diagnosed and recommendations for when to see a fertility specialist, success rates, financial programs, treatment options, and much more. SGF New York's fertility seminars are free and include a complimentary physician consult that can be scheduled onsite.

SGF New York's donor egg treatment seminars will provide in-depth look into SGF's internationally renowned Donor Egg Treatment Program, the largest program in the nation. SGF, home to more than 8,000 babies born from donor egg treatment, is one of only a few centers in the nation that recruits, selects, and prescreens (medically, psychologically, and genetically) its own ready-to-cycle egg donors prior to making them available on their donor registry. Further, SGF offers exclusive 100% refund guarantee programs not only for IVF but donor egg treatmenta significant differentiator among other programs in the area. All attendees will receive a complimentary physician consult and one lucky attendee will receive $1,000 off a future donor egg treatment at SGF New York.

SGF New York's egg freezing seminars will offer attendees a deep dive into SGF's track record with egg freezing, a fertility-preserving option that's growing in popularity at an unprecedented 20 percent per year, nationally, with even higher growth rates in New York City and surrounding areas. SGF holds the spot as one of the top five egg freezing programs in the U.S., and the number of women choosing egg freezing at SGF continues to rise. The seminar will cover SGF's success rates, with SGF being one of only a few centers in the nation with published success rates for women who return to use their frozen eggs. In addition, the seminar will cover what to expect during fertility testing to determine candidacy for egg freezing, what to expect during an egg freezing cycle, financial programs, SGF's refund guarantees for egg freezing, and much more. All attendees will be entered into a raffle where one lucky attendee will receive $1,000 off a future egg freezing treatment cycle at SGF New York.

All SGF New York seminars will be hosted in their new 15,300 square foot space in New York City, conveniently located at 110 East 60th Streetminutes from nine NY subway stations providing easy access from all boroughs as well as Westchester, Long Island, and Connecticut, and steps from Bloomingdales, Rockefeller Center, Central Park, and The Plaza Hotel.

The SGF New York location is home to physician offices for patient consultations, SGF's ninth embryology lab, a spacious operating room, embryo transfer room, and recovery bays. Patients benefit from having an onsite dedicated andrology laboratory for sperm preparation and an onsite endocrinology lab for processing bloodwork.

Services available in SGF New York include fertility testing and diagnosis, including semen analysis; non-invasive fertility options such as ovulation induction and intrauterine insemination (IUI); in vitro fertilization (IVF); donor egg treatment; preimplantation genetic testing; fertility preservation through egg freezing; and LGBTQ family building.

Story continues

While all SGF in-person and online events are complimentary, interested parties must register to attend by visiting the SGF calendar of events.

Dr. Anate Brauer earned her medical degree from the George Washington University School of Medicine. She completed her residency training in obstetrics and gynecology at New York Presbyterian Hospital-Weill Cornell Medical Center, and her fellowship training in reproductive endocrinology and infertility at Weill Cornell Medical College in New York, NY. Dr. Brauer is board certified in obstetrics and gynecology and reproductive endocrinology and infertility.

Dr. Singer earned his medical degree from the Sackler School of Medicine and his Master of Business Administration in Health Care Management from Hofstra Zarb School of Business. He completed his residency training in obstetrics and gynecology at Lenox Hill Hospital in New York, NY, where he also served as Chief Resident, and his fellowship training in reproductive endocrinology and infertility fellowship at Weill Cornell Medical College in New York, NY. Dr. Singer is board certified in obstetrics and gynecology and reproductive endocrinology and infertility.

To make an appointment in New York City, call 212-203-4826 or submit this brief form.

To schedule an appointment at any of SGF's other 35 domestic locations, call the SGF New Patient Center at 888-761-1967.

About Shady Grove Fertility (SGF) SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and counting. With 36 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including treatment guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

SOURCE Shady Grove Fertility

Go here to read the rest:
Shady Grove Fertility (SGF) New York Announces Nine Upcoming Patient Education Events in its New Manhattan Location, Hosted by Drs. Anate Brauer and...

Embryology

Assisted Reproductive Technology Market would Witness an Annual Increase of Around 6.3% in 2020-2025 – MENAFN.COM

January 8, 2020 medical

(MENAFN - Market Research HUB) Reproduction segment is currently blooming. The major factor responsible for its growth are improved access to fertility clinics and fertilization technology advancements. Different organizations have come forward to encourage people to avail reproductive assistance services. Angels of Hope Foundation, BabyQuest Foundation and Pay-it-Forward Foundation are some of the organizations in US that offer grants to make fertility treatment affordable as it is cost-intensive which discourages the general public. Reproductive outcomes from such services have been positive. This increases the adoption rate of assistive reproductive technologies like IVF and IUI. Technologies have significantly increased the number of treatments that are available for infertility.Modern lifestyle induces productivity issuesIn many economies across the globe, same sex marriages are made legal. Such marriages are eyed as prominent revenue source for the global assistive reproductive technology market. Latest Fact.MR report forecasts that the revenue of assistive reproductive technology will increase by 6.3% by the end of 2020.Modern lifestyle has induced stress in people. This adversely effects the reproductive capacity in men and women, compelling them to divert towards assistive reproductive technologies. Centers for Disease Control and Prevention (CDC) give the data that 82% ART cycle induced pregnancies are based on use of fresh non-donor eggs. The major factor driving this rate is the desire to have a child with eggs form one person. Fresh non-donor eggs are trending as the medium for using assistive technology. It is primarily used by women below the age of 35. Major factors like late family planning and increase in prevalence of chronic diseases such as cancer cause infertility issues. Medical freezing is getting recommended by medical professionals for women to reduce the risks of infertility.Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4393Employers offer perks and incentives to employeesMajor employers are addressing infertility issues in their employees. They have come up with perks and incentives to encourage employees to store eggs so that they do not undergo infertility issues in future. These factors are expected to surge the demand for frozen non-donor procedures. Assistive reproductive technology is used to treat infertility using many treatment cycles, which makes the treatment very expensive.Fertility clinics have identified the scope of opportunities in treatment of productivity issues. They have introduced one stop solutions that include diagnostic as well as the treatment. Major stake holders are investing towards development of embryology labs that are used to ensure safe and efficient gamete handling. Medical professionals are preferring fertility clinics of treatment as these spaces offer quality service and are laced with advanced technologies. Fact.MR report predicts that fertility clinics can generate US$16.8Bn revenue by the end of the year 2020.Different attitude is adopted towards assisted reproductive technology in different regions. This happens because such technologies get different implementation in terms of reimbursement facilities, patient outcomes and cost in different regions. Fact.MR report highlights the fact the 53% of the Netherland's population ops for quality reproductive treatments and chooses to even go abroad for it. Cross-border reproductive care is highly popular in European countries.Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=4393

MENAFN0801202000703446ID1099523637

Embryology

Fertility Clinics Scoring Well in Assisted Reproductive Technology Market – Voice of Reports

January 8, 2020 medical

Reproduction segment is currently blooming. The major factor responsible for its growth are improved access to fertility clinics and fertilization technology advancements. Different organizations have come forward to encourage people to avail reproductive assistance services. Angels of Hope Foundation, BabyQuest Foundation and Pay-it-Forward Foundation are some of the organizations in US that offer grants to make fertility treatment affordable as it is cost-intensive which discourages the general public. Reproductive outcomes from such services have been positive. This increases the adoption rate of assistive reproductive technologies like IVF and IUI. Technologies have significantly increased the number of treatments that are available for infertility.

Modern lifestyle induces productivity issues

In many economies across the globe, same sex marriages are made legal. Such marriages are eyed as prominent revenue source for the global assistive reproductive technology market. Latest Fact.MR report forecasts that the revenue of assistive reproductive technology will increase by 6.3% by the end of 2020.

Modern lifestyle has induced stress in people. This adversely effects the reproductive capacity in men and women, compelling them to divert towards assistive reproductive technologies. Centers for Disease Control and Prevention (CDC) give the data that 82% ART cycle induced pregnancies are based on use of fresh non-donor eggs. The major factor driving this rate is the desire to have a child with eggs form one person. Fresh non-donor eggs are trending as the medium for using assistive technology. It is primarily used by women below the age of 35. Major factors like late family planning and increase in prevalence of chronic diseases such as cancer cause infertility issues. Medical freezing is getting recommended by medical professionals for women to reduce the risks of infertility.

Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4393

Employers offer perks and incentives to employees

Major employers are addressing infertility issues in their employees. They have come up with perks and incentives to encourage employees to store eggs so that they do not undergo infertility issues in future. These factors are expected to surge the demand for frozen non-donor procedures. Assistive reproductive technology is used to treat infertility using many treatment cycles, which makes the treatment very expensive.

Fertility clinics have identified the scope of opportunities in treatment of productivity issues. They have introduced one stop solutions that include diagnostic as well as the treatment. Major stake holders are investing towards development of embryology labs that are used to ensure safe and efficient gamete handling. Medical professionals are preferring fertility clinics of treatment as these spaces offer quality service and are laced with advanced technologies. Fact.MR report predicts that fertility clinics can generate US$16.8Bn revenue by the end of the year 2020.

Different attitude is adopted towards assisted reproductive technology in different regions. This happens because such technologies get different implementation in terms of reimbursement facilities, patient outcomes and cost in different regions. Fact.MR report highlights the fact the 53% of the Netherlands population ops for quality reproductive treatments and chooses to even go abroad for it. Cross-border reproductive care is highly popular in European countries.

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=4393

I am Randy Morales and I focus on breaking news stories and ensuring we (Voice of Report) offer timely reporting on some of the most recent stories released through market wires about Earnings sector.

I have formerly spent over 3 years as a trader in U.S. Stock Market and is now semi-stepped down. I work on a full time basis for News Cast Report specializing in quicker moving active shares with a short term view on investment opportunities and trends.

See the original post:
Fertility Clinics Scoring Well in Assisted Reproductive Technology Market - Voice of Reports

Neuroscience

Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia – A Free Webinar from the Brain & Behavior Research Foundation -…

January 8, 2020 medical

New York, Jan. 08, 2020 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation is hosting a free webinar Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia on Tuesday, January 14, 2020, from 2pm to 3pm ET. Gregory A. Light, Ph.D., University of California, San Diego, will be the presenter.

Dr. Light will describe precision medicine trials his team has conducted which significantly reduced symptoms and improved cognitive and daily functioning in patients with chronic psychosis in a real-world setting: a long-term community inpatient facility. They also found that reliable, easy-to-obtain signatures of brain-wave activity recorded at the outset of treatment can be used to identify which patients are most likely to benefit (or not) from treatments. This work ultimately aims to develop personalized biomarker assessment tools to deliver the right treatment to the right person at the right time, to improve outcomes among the millions of people with psychotic disorders, most notably schizophrenia.Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation and Host and Executive Producer of the public television series Healthy Minds, will be the moderator. Join by phone or on the web at bbrf.org/januarywebinar.

This webinar is part of a series of free monthly Meet the Scientist webinars on the latest developments in psychiatry offered by the Brain & Behavior Research Foundation.

The Brain & Behavior Research Foundation The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness. These illnesses include addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, and schizophrenia, as well as research on suicide prevention. Since 1987, the Foundation has awarded more than $408 million to fund more than 4,800 leading scientists around the world, which has led to over $4 billion in additional funding. 100% of every dollar donated for research is invested in research grants. BBRF operating expenses are covered by separate foundation grants. BBRF is the producer of the Emmy nominated public television series Healthy Minds with Dr. Jeffrey Borenstein, which aims to remove the stigma of mental illness and demonstrate that with help, there is hope.

Read the original:
Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia - A Free Webinar from the Brain & Behavior Research Foundation -...